<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81973">
  <stage>Registered</stage>
  <submitdate>19/04/2007</submitdate>
  <approvaldate>15/05/2007</approvaldate>
  <actrnumber>ACTRN12607000261415</actrnumber>
  <trial_identification>
    <studytitle>A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP)</studytitle>
    <scientifictitle>A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP)</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Erythropoietic Protoporphyria</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>CUV1647 (16 mg/implant) contained in a poly(D,L-lactide-co-glycolide) implant core.  The implant is fully bioresorbable and implanted subcutaneously.  Drug is released from the active implant over 10 to 15 days.  The study design consists of two parallel study arms with crossover between treatments every 60 days for 360 days.  There is no wash out period in this study.</interventions>
    <comparator>Placebo poly(D,L-lactide-co-glycolide) implant (without drug).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determine whether CUV1647 can reduce the number of phototoxic reactions in patients with EPP</outcome>
      <timepoint>Patients record the number of reactions in a diary card completed every day and assessed every 30 days.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Determine whether CUV1647 can reduce the severity of phototoxic reactions in patients with EPP</outcome>
      <timepoint>Patients record the severity of reactions in a diary card completed every day and assessed every 30 days.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Determine whether CUV1647 can increase the duration of sunlight tolerated by EPP patients. </outcome>
      <timepoint> Patients record the amount of time spent in sunlight in the diary card which is completed every day and reviewed every 30 days.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine whether CUV1647 increases melanin density in the skin at specified body sites. </outcome>
      <timepoint> Melanin density is measured every 30 days.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the safety and tolerability of CUV1647 by measuring treatment-emergent adverse events (TEAEs).  </outcome>
      <timepoint> TEAEs will be recorded daily in the patient diary card and assesed every 30 days.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine whether CUV1647 can improve the quality of life (QoL) of EPP patients.  </outcome>
      <timepoint>QoL is measured with the SF36 v2 questionnaire every 60 days.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects with a positive diagnosis of EPP</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>EPP patients with significant hepatic involvement
Any other photodermatosis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Stratified by centre, simple randomisation by using a randomisation table created by a computer software (i.e., computerised sequence generation).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The study is blinded to both treating doctor and patient.  The study design consists of two parallel study arms with crossover between treatments every 60 days</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/06/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3000</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duesseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Clinuvel Pharmaceuticals Limited</primarysponsorname>
    <primarysponsoraddress>11/330 Collins St Melbourne VIC 3000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Clinuvel Pharmaceuticals Limited</fundingname>
      <fundingaddress>11/330 Collins St Melbourne VIC 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if there is a difference between the number and severity of phototoxic reactions that occurr in patients with Erythropoietic Protoporphyria (EPP) treated with CUV1647 and placebo.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethik-Kommission der beiden Stadtspitaler Triemli und Waid Zuerich</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>STZ 07/07</hrec>
      <ethicsubmitdate />
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Directorate Level 6 East, Main Block Royal Melbourne Hospital City Campus Grattan Street PARKVILLE VIC 3050</ethicaddress>
      <ethicapprovaldate>18/07/2007</ethicapprovaldate>
      <hrec>EC00243</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Comite de Protection des Personnes Ile de France VIII</ethicname>
      <ethicaddress>Hospital Ambroise Pare 
9, avenue Charles de Gaulle
92100 Boulogne-Billancourt</ethicaddress>
      <ethicapprovaldate>24/04/2008</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>France</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Comitato Etico I.F.O.</ethicname>
      <ethicaddress>via Chianesi, 53
00128 Roma</ethicaddress>
      <ethicapprovaldate>30/07/2007</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethikkommission an der Med. Fakultat der Heinrich-Heine-Univ. Duesseldorf</ethicname>
      <ethicaddress>Kinderklinik Geb. 13.41 
Moorenstr. 5 
40225 Duesseldorf</ethicaddress>
      <ethicapprovaldate>2/06/2008</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Germany</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Regionala etikprovningsnamnden i Stockholm</ethicname>
      <ethicaddress>FE 289
Stockholm
171 77</ethicaddress>
      <ethicapprovaldate>7/05/2008</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Sweden</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-centre Research Ethics Committee for Wales</ethicname>
      <ethicaddress>4th Floor, Churchill House 
Churchill Way 
Cardiff CF10 2TW</ethicaddress>
      <ethicapprovaldate>17/06/2008</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>United Kingdom</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Medisch Ethische Toetsings Commissie Erasmus MC</ethicname>
      <ethicaddress>Erasmus MC/faculteit, 
Kamer Fd-209, 
Postbus 2040, 
3000 CA ROTTERDAM</ethicaddress>
      <ethicapprovaldate>18/09/2008</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Netherlands</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dennis Wright</name>
      <address>Clinuvel Pharmaceuticals Limited 11/330 Collins St Melbourne VIC 3000</address>
      <phone>+61 3 96604900</phone>
      <fax />
      <email>clinicaltrials@clinuvel.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dennis Wright</name>
      <address>Clinuvel Pharmaceuticals Limited 11/330 Collins St Melbourne VIC 3000</address>
      <phone>+61 3 96604900</phone>
      <fax />
      <email>clinicaltrials@clinuvel.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jessica Jia</name>
      <address>Clinuvel Pharmaceuticals Limited 11/330 Collins St Melbourne VIC 3000</address>
      <phone>+61 3 9660 4900</phone>
      <fax>+61 3 9660 4999</fax>
      <email>clinicaltrials@clinuvel.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>